Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results [Financial Post (Toronto, Ontario, Canada)]
Aditxt, Inc. (ADTX)
Company Research
Source: Financial Post
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans HALIFAX, Nova Scotia, June 25, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2024 (“FYE 2024”), and provided an update on the Company's strategy for fiscal 2025. All figures are stated in Canadian dollars unless otherwise stated. Article content “Notably, during this past fiscal year, the Company's most advanced asset LIKMEZ (ATI-1501), received U.S. Food and Drug Administration (“FDA”) approval, and together with our partner, Saptalis launc
Show less
Read more
Impact Snapshot
Event Time:
ADTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADTX alerts
High impacting Aditxt, Inc. news events
Weekly update
A roundup of the hottest topics
ADTX
News
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024Business Wire
- Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt [Yahoo! Finance]Yahoo! Finance
- Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by AditxtBusiness Wire
- Aditxt and Evofem partner to launch endometriosis diagnostic in 2025 [Yahoo! Finance]Yahoo! Finance
- Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025Business Wire
ADTX
Sec Filings
- 9/23/24 - Form 8-K
- 9/16/24 - Form 424B3
- 9/16/24 - Form EFFECT
- ADTX's page on the SEC website